Enhance your well-being with thyroid optimization to support hormone balance. Learn vital tips for improving thyroid function.

Abstract

As a clinician who lives without a thyroid and as an integrative practitioner, I have spent decades studying why so many people feel hypothyroid despite “normal labs.” In this educational post, I walk you through what I have learned treating thousands of patients: why TSH is not the whole story, how free T3 and reverse T3 determine tissue-level thyroid action, and how conversion bottlenecks (stress, inflammation, micronutrient deficits, insulin resistance) derail metabolism. I explain when levothyroxine is enough, when combination therapy (T4+T3) or desiccated thyroid makes sense, and how to time and interpret labs accurately—especially with T3-containing medications. I also share how integrative chiropractic care fits within a modern, evidence-based plan to optimize autonomic balance, reduce pain and inflammation, improve movement, and enhance endocrine resilience. Drawing on leading research and the outcomes I document on my clinical platforms, I lay out a practical, physiology-first pathway to restore energy, weight regulation, thermoregulation, mood, cognition, and cardiometabolic health.

Why Thyroid Health Matters Now

When patients tell me, “I live without a thyroid,” I mean it literally. In my early adulthood, I have seen them undergo thyroid ablation that left them fully dependent on hormone replacement. That experience shapes how I listen to patients, how I read labs, and how I design care in my integrative chiropractic practice.

Across more than 9,000 patient cases in my EMR, I have seen a repeating pattern: people who are “biochemically euthyroid” on paper still feel profoundly unwell. In practice, I routinely address the full spectrum of thyroid imbalance. Patients describe classic hypothyroid effects such as debilitating fatigue, cold intolerance, constipation, weight gain, brain fog, slowed cognition, hair thinning, dry skin, low mood or depression, muscle weakness, and exercise intolerance. Others experience disruptive hyperthyroid manifestations, including unintended weight loss despite increased appetite, heat intolerance, anxiety or irritability, rapid heartbeat or palpitations, diarrhea, tremors, restlessness, insomnia, and excessive sweating.

Over the last decade-plus, I have asked a simple question: If TSH is “perfect,” why doesn’t the person feel well? By incorporating precise chiropractic adjustments to optimize spinal alignment, nervous system function, and autonomic balance, I help support endocrine regulation and close the gap between lab values and genuine vitality. The answer lives in the physiology of T4-to-T3 conversion, the role of reverse T3 (rT3), the mitochondria, and the stress–inflammation network that sets the tone for metabolic function.

What follows is a practical, evidence-guided journey through the science and the real-world methods that consistently help my patients feel and function better.

Thyroid Physiology Explained: Why TSH Is Not Enough

The hypothalamic–pituitary–thyroid (HPT) axis sets the stage: the hypothalamus secretes TRH, the pituitary secretes TSH, and the thyroid gland releases primarily T4 with a smaller proportion of T3. Yet the bioactive hormone is T3, which binds nuclear thyroid receptors and drives mitochondrial biogenesis, ATP production, thermogenesis, and transcription of genes that govern energy and tissue renewal (Yen, 2019).

Key points that determine how you feel:

• T4 is a prohormone. Roughly 80% of active T3 is produced in peripheral tissues by deiodinase enzymes (DIO1/DIO2). If conversion falters, tissues become T3-deficient even if T4 looks normal.
• T3 is the metabolic “on switch.” It increases mitochondrial oxidative phosphorylation, oxygen consumption, Na+/K+-ATPase activity, and lipolysis.
• Reverse T3 (rT3) is a physiologic brake. Under stress, illness, inflammation, caloric restriction, or high T4 loads, DIO3 shunts T4 to rT3. rT3 binds to receptors without activating them, thereby reducing T3 signaling.
• The pituitary is special. It relies on DIO2 to locally convert T4 to T3, so the pituitary can “see” enough T3 to suppress TSH, while the rest of the body remains T3-poor. This is why TSH alone can mislead during therapy (Peterson, McAninch, & Bianco, 2018).

What this means clinically:

• You can have a “normal” or even low TSH, “adequate” free T4, and still be functionally hypothyroid if free T3 is low or rT3 is high (Jonklaas et al., 2019).
• Patients treated with levothyroxine (T4) often have normalized TSH but lower serum T3 than matched controls, with persistent symptoms (Hoang et al., 2013; Peterson et al., 2018).
• Genetic variation (e.g., DIO2 Thr92Ala) may limit intracellular T3 generation in some patients, which may explain why T4-only therapy is insufficient for a subset (Panicker et al., 2009).

In practice, I evaluate TSH, free T4, free T3, and reverse T3, and I correlate labs with symptoms, vitals, and function. That fuller picture puts us closer to the tissue-level truth.

The Metabolic Mismatch: Why “Normal Labs” Can Coexist With Weight Gain

I have watched obesity rates climb across the United States. If thyroid replacement consistently restored metabolism, more of my patients would stabilize. Instead, I see a metabolic mismatch: normalized TSH, adequate T4, but insufficient T3 where it matters—the tissue.

Mechanisms that drive the mismatch:

• Inflammation and stress elevate IL-6/TNF-? levels and activate DIO3, thereby increasing rT3 and lowering T3 (Peeters, 2017).
• Mitochondrial inefficiency in low-T3 states reduces oxidative phosphorylation and thermogenesis, lowering resting energy expenditure (REE).
• Insulin resistance and glycotoxicity suppress DIO1, reduce GLUT4 translocation, and favor lipid storage.
• Sarcopenia and activity intolerance worsen when T3 is low, reducing non-exercise activity thermogenesis (NEAT).

Clinical takeaway: If fatigue, cold intolerance, constipation, and weight gain persist on T4 with a “good” TSH, we must ask whether tissues are receiving adequate T3 and whether systemic inflammation, nutrient deficits, sleep loss, or insulin resistance are blocking conversion.

Three Faces of Hypothyroidism: Production, Conversion, and Receptor-Level Issues

To simplify clinical thinking, I describe three patterns:

• Type 1: Production failure

• • Hashimoto’s, post-thyroidectomy, radioiodine, or primary gland failure. TSH elevated, T4/T3 low. TSH is most helpful here.

• Type 2: Conversion impairment and high rT3

• • Stress, inflammation, insulin resistance, dieting, depression, nutrient deficits. TSH and T4 are often “normal,” but free T3 is low, and rT3 is high. Symptoms mirror hypothyroidism despite “normal” TSH. This is common.

• Type 3: Receptor site insensitivity

• • Rare but real—profound rT3 elevation, receptor-level variations, or chronic inflammation. Labs may be unremarkable; diagnosis is clinical and driven by response to lowering rT3 and careful T3 support.

Only Type 1 reliably shows an abnormal TSH that lines up neatly with symptoms. Types 2 and 3 are where TSH becomes an unreliable compass.

The Case for Measuring What Matters: A Precision Lab Strategy

When a new patient arrives saying,”My TSH is fine, but I feel awful”, I ask for a panel that reflects physiology:

• Core thyroid markers: TSH, free T4, free T3, reverse T3 (when on T4 therapy or when conversion issues are suspected)
• Autoimmunity: TPO and thyroglobulin antibodies when indicated
• Micronutrients: Ferritin/iron panel, selenium, zinc, vitamin D
• Metabolic context: Fasting insulin, HbA1c, lipids
• Inflammation and stress: hs-CRP; sleep assessment; sometimes morning cortisol trends
• Function: Resting heart rate and blood pressure, HRV (when available), grip strength, and 6-minute walk; body composition

I interpret these data alongside symptom inventories and physical findings. If free T3 is low or rT3 is high in symptomatic patients, I look for conversion blockers and consider a T3-containing regimen—with careful monitoring.

References: Is a normal TSH synonymous with euthyroidism in levothyroxine monotherapy? (Peterson et al., 2018); Guidelines for the treatment of hypothyroidism (Jonklaas et al., 2014).

T4-Only vs Combination Therapy: When Each Approach Makes Sense

Why levothyroxine (T4) works for many:

• Physiologically, the thyroid secretes mostly T4, and many patients convert adequately to T3.
• T4 has a long half-life, stable pharmacokinetics, and strong evidence for overt hypothyroidism (Jonklaas et al., 2014).

Why do some patients need more than T4:

• Persistent symptoms with low free T3 and/or high rT3, despite optimized TSH.
• DIO2 polymorphisms potentially reduce intracellular T3 generation (Panicker et al., 2009).
• Inflammation, stress, caloric restriction, or illness that push conversion toward rT3.

Options and how I use them:

• Add liothyronine (T3) in small, divided doses (e.g., 2.5–5 mcg twice daily) to raise free T3 to the middle or upper half of the reference range, while monitoring vital signs and symptoms (Hoang et al., 2013).
• Desiccated thyroid (DTE) provides a fixed T4:T3 ratio and may align more closely with some patients’ physiology. Evidence is mixed overall; a meaningful subset prefers and feels better on DTE or T4+T3 combinations (Hoang et al., 2013).
• Compounded T4/T3 allows fine-tuning ratios and excipients for sensitive patients.

My protocol is individualized: start with T4 optimization, reassess in 6–8 weeks, and if symptoms persist with low free T3 or high rT3, I consider adding T3 or trialing DTE. I monitor TSH, free T4, free T3, rT3, SHBG, lipids, resting heart rate, and blood pressure, and I track energy, bowels, sleep, HRV, and weight.

References: Desiccated thyroid extract compared with levothyroxine (Hoang et al., 2013); Common variation in DIO2 and well-being on therapy (Panicker et al., 2009).

Timing and Interpretation of Labs on T3-Containing Therapy

Managing T3 without timing your labs is guesswork. Oral T3 peaks at ~2–3 hours post-dose and then declines over 6–8 hours. To avoid chasing peaks, my clinic standard is a 5–6-hour post-morning-dose blood draw for any patient on DTE or T4+T3. This window captures a stable, clinically relevant midpoint—less distorted by peaks and more reflective of how you function during the day.

Practical standards we enforce:

• Keep lab timing consistent across all follow-ups.
• If taking split doses, draw labs just before the afternoon dose to capture a steady level.
• Use wearables like Apple Watch to track resting pulse and correlate with potential T3 peaks; if palpitations cluster ~2 hours post-dose, we refine timing or split the dose.

Why this matters: Comparable timing yields reliable data, supports safer titration, and accelerates symptom relief (Jonklaas et al., 2014; Wiersinga, 2021).

Reverse T3: The Brake That Becomes a Block

Reverse T3 (rT3) is an isomer of T3 that fits the receptor without activating it. In stress, illness, caloric restriction, or high T4 exposure, DIO3 ramps up, pushing T4 toward rT3 and away from T3. Chronically elevated rT3 acts like a functional blockade, leaving patients cold, constipated, fatigued, and foggy even when “labs are normal.”

How I lower rT3 in practice:

• Reduce stress load and improve sleep by implementing breathwork and vagal tone practices.
• Correct micronutrient deficits: selenium, zinc, iron; optimize vitamin D.
• Improve insulin sensitivity with nutrition and progressive resistance training.
• In select cases, titrate T3 and reduce T4 load to relieve receptor blockade while monitoring vitals and symptoms.

In my cohorts, rT3 reduction often aligns with warmer extremities, smoother digestion, better mood and cognition, and improved exercise tolerance (Peeters, 2017; Maia et al., 2011).

Thyroid Dysfunction-Video

The Gut–Liver–Thyroid Axis and Nutrient Cofactors

About 20% of T4-to-T3 conversion occurs outside the thyroid in the liver and gut. These organs are pivotal to hormone activation and recycling.

• Liver: Deiodinase activity is sensitive to NAFLD, alcohol, and medications. Supporting liver health with anti-inflammatory nutrition, weight management, and targeted nutraceuticals enhances conversion.
• Microbiome: Gut bacteria deconjugate thyroid hormones and influence enterohepatic cycling; dysbiosis can worsen inflammation and blunt conversion.
• Nutrients:

• • Selenium supports deiodinase activity and may reduce thyroid antibody levels in some patients.
  • Zinc facilitates thyroid receptor function and conversion.
  • Iron is critical for thyroid peroxidase activity and overall energy production.
  • Iodine is essential for synthesis, but in autoimmune thyroiditis, it requires careful, individualized repletion, alongside selenium, to avoid oxidative stress.

Clinical actions I take:

• Assess ferritin/iron, selenium, zinc, vitamin D, and digestion.
• Use a protein-centered, anti-inflammatory diet with polyphenols, omega-3s, and fiber.
• Integrate breathing mechanics and thoracic mobility work to support lymphatic and visceral dynamics, aiding digestion and systemic recovery.

References: Thyroid hormone deiodinases in human physiology and disease (Maia et al., 2011); Iodine nutrition and thyroid disease (Pearce et al., 2018).

Mitochondria, Energy, and the Stress Axis

Thyroid hormones regulate mitochondrial biogenesis via PGC-1? and enhance electron transport chain capacity. In low-T3 states, ATP production declines, thermogenesis drops, and oxidative stress signaling can drift off course (Yen, 2019). Simultaneously, chronic stress elevates cortisol and catecholamines, increasing DIO3, raising rT3, and worsening insulin resistance.

Interventions that consistently help my patients:

• Normalize thyroid hormone signaling with appropriate dosing and timing.
• Implement progressive resistance and zone 2 aerobic training to stimulate mitochondrial proliferation and improve insulin sensitivity.
• Prioritize sleep and circadian alignment to tighten endocrine rhythms.
• Apply integrative chiropractic care to reduce pain and sympathetic tone, improving movement efficiency, HRV, and stress resilience.

How Integrative Chiropractic Care Fits Into Thyroid Treatment

As a DC and APRN, I see the thyroid through the lens of a neuroendocrine–metabolic network. Mechanical stress, autonomic imbalance, and chronic pain amplify cortisol and cytokine levels, which impair T4-to-T3 conversion. Addressing these drivers multiplies the impact of endocrine therapy.

What I do in the clinic:

• Autonomic modulation: Gentle spinal manipulation and soft tissue work to improve cervical and thoracic mobility and enhance parasympathetic tone. Patients frequently show improved HRV and reduced stress reactivity.
• Pain reduction and movement restoration: By resolving joint restriction, myofascial adhesions, and segmental dysfunction, we lower nociceptive input and systemic stress, support better sleep, and enable regular exercise—all of which enhance deiodinase activity.
• Breathing and rib mechanics: Optimizing diaphragmatic function and rib cage motion improves lymphatic and venous return, gastroesophageal function, and recovery, thereby facilitating nutrient delivery and hormone transport.
• Exercise prescription: I program graded resistance and aerobic training to improve insulin sensitivity, raise REE, and increase T3 receptor expression in muscle.

Clinical observations from my practice and platforms at the Personal Injury Doctor Group and LinkedIn indicate that combining precise hormone strategies with chiropractic-integrative care moves the needle more than either approach alone.

Learn more about my clinical observations:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Cardiometabolic and Cognitive Connections: Why T3 Often Predicts Outcomes

Beyond metabolism and weight, free T3 often predicts outcomes in heart and brain health more reliably than TSH or T4:

• In heart disease and heart failure, low T3 predicts higher mortality and adverse remodeling; TSH and T4 often do not (Iervasi et al., 2003; Pingitore et al., 2005).
• In critical illness and ARDS, low T3 correlates with higher mortality and prolonged ventilation (Grebennikova, Korneev, & Zubarev, 2020).
• In neurology and psychiatry, low T3 aligns with cognitive decline and worsened mood states; T3 augmentation may benefit select depressive disorders under supervision (Bauer, Goetz, Glenn, & Whybrow, 2008).

Physiology explains this: T3 maintains sarcoplasmic reticulum Ca2+ handling (SERCA2a), myosin heavy chain expression, inotropy, endothelial nitric oxide signaling, and mitochondrial ATP turnover. Low T3 shifts the heart toward an energy-conserving phenotype with poorer contractility and perfusion (Klein & Danzi, 2007; Ojamaa et al., 2010).

My clinical practice mirrors the literature: when free T3 is optimized and rT3 reduced under careful monitoring, patients frequently report improved exercise tolerance, warmer extremities, better mood and cognition, and steadier cardiovascular performance.

Practical Protocol: Step-by-Step Approach I Use

I organize care around measurable physiology and reproducible routines.

• Assessment

• • Detailed symptoms: fatigue, cold intolerance, bowel habits, hair/skin changes, mood/cognition, sleep, palpitations.
  • Vitals and function: resting pulse, BP, HRV (when available), grip strength, 6-minute walk; body composition.
  • Labs: TSH, free T4, free T3, reverse T3 when indicated; TPO/TgAb; ferritin/iron; selenium, zinc, vitamin D; fasting insulin, HbA1c; hs-CRP; lipids.
  • Medication and supplement audit for absorption blockers (iron, calcium, fiber, PPIs, and biotin) that can distort assay results.

• Initial interventions

• • Nutrition: Protein adequacy (?1.2–1.6 g/kg/day in most adults), omega-3s, anti-inflammatory pattern; limit ultra-processed foods.
  • Micronutrients: Ensure selenium and zinc sufficiency; replete iron if ferritin is low; optimize vitamin D.
  • Sleep and stress: Circadian routines, morning light, breathwork, mindfulness, and pain reduction.
  • Movement and chiropractic: Progressive resistance 2–3 times weekly; zone 2 cardio 2–3 times weekly; spinal and soft tissue care focused on autonomic balance and gait efficiency.

• Medication strategy

• • Optimize T4 first when appropriate; reassess in 6–8 weeks.
  • If free T3 remains low or rT3 high with persistent symptoms, add liothyronine (T3) in divided doses or consider DTE or compounded T4/T3.
  • For T3-containing regimens, standardize labs 5–6 hours after the morning dose; aim for free T3 in the mid-to-upper reference range without signs of hyperthyroidism.
  • Split dosing (BID, sometimes TID) to reduce peaks and side effects.

• Monitoring and safety

• • Recheck free T3, free T4, TSH (and rT3 as needed) in 6–8 weeks after dose changes.
  • Track pulse, BP, sleep quality, bowel function, and activity tolerance.
  • For at-risk patients, monitor bone density and arrhythmia risk; co-manage with cardiology when warranted.

• Iteration

• • Adjust dosing and lifestyle support based on symptoms and standardized lab results.
  • Refine movement and manual therapy targets to maintain autonomic balance and reduce inflammatory load.

Real-World Vignettes From My Practice

• The “normal TSH, abnormal life” case

• • A middle-aged patient had TSH of 2.1 mIU/L, mid-range free T4, low-normal free T3, and elevated rT3—classic fatigue, constipation, and weight gain. We optimized T4, repleted selenium and iron, and used targeted manual therapy to improve diaphragmatic function and thoracic mobility. Energy improved by patient report (~40%), HRV trended up, and constipation resolved. A cautious addition of T3 normalized rT3 and increased resting energy expenditure.

• The athletic patient with thyroid autoimmunity

• • Training was limited by shoulder and low back pain, as well as low T3. We stabilized T4 therapy, reduced inflammation through nutrition, addressed scapulothoracic and lumbopelvic mechanics, and added progressive strength training. Free T3 rose into the upper-normal range as inflammation markers fell; training volume and lean mass increased.

• Peak-related palpitations on DTE

• • A professional felt “wired” at 8–9 a.m. on a single, higher morning DTE dose. Apple Watch data showed pulse spikes ~2 hours post-dose. We split the dose; palpitations resolved, cognition remained sharp, and 5–6 hours post-dose, free T3 stabilized in the upper midrange.

You can see more of my case-informed insights at my clinical platforms:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Safety, Risks, and How I Keep Therapy On Track

The goal is tissue euthyroidism—not a particular TSH level alone. I screen, counsel, and monitor to protect bone and cardiovascular health.

• Over-replacement risks: palpitations, anxiety, and bone loss in susceptible populations. I titrate slowly, track vitals, and monitor bone density in high-risk groups.
• Under-replacement risks: dyslipidemia, weight gain, depression, poor exercise tolerance.
• Absorption pitfalls: Calcium, iron, certain fibers, timing of coffee, PPIs, and hypochlorhydria can impair absorption; biotin can interfere with immunoassays. I standardize routines and use liquid or soft-gel T4 when needed (Virili et al., 2016).
• Suppressed TSH on therapy: In carefully monitored patients with physiologic free T3/free T4 levels and no signs of hyperthyroidism, a low TSH is not, by itself, proof of overtreatment (Biondi & Cooper, 2008; Flynn et al., 2010). I use clinical status and full labs to guide dosing, not TSH alone.

Why This Integrated Model Works

• TSH is a screening tool; it does not consistently track thyroid tissue action on therapy.
• Free T3 correlates with mitochondrial output, vascular function, mood, and performance—bringing it into the optimal physiologic zone resolves symptoms for many.
• Reverse T3 is a modifiable brake; lowering it restores receptor access for T3 and unlocks metabolic capacity.
• Integrative chiropractic care reduces pain-driven sympathetic overactivity, improves autonomic balance, aids digestion and lymphatic flow, and supports movement—lowering the physiologic burden that suppresses DIO1 and drives DIO3.
• Personalized protocols beat one-size-fits-all algorithms. When we individualize dosing, timing, nutrients, sleep, and movement—and we standardize lab interpretation windows—patients recover faster and sustain gains.

If you have persistent hypothyroid symptoms with “normal” labs, it is time to look deeper. With careful evaluation and an integrative plan, we can restore metabolism safely, durably, and evidence-informed.

References

• Biondi, B., & Cooper, D. S. (2008). The clinical significance of subclinical thyroid dysfunction. Journal of Clinical Endocrinology & Metabolism, 93(1), 31–46.
• Flynn, R. W. V., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010). Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology & Metabolism, 95(1), 186–193.
• Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. (2013). Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism. Thyroid, 23(4), 377–383.
• Iervasi, G., Molinaro, S., Landi, P., et al. (2003). Low T3 syndrome: A strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713.
• Jonklaas, J., Bianco, A. C., Bauer, A. J., et al. (2014). Guidelines for the treatment of hypothyroidism. Thyroid, 24(12), 1670–1751.
• Jonklaas, J., et al. (2019). Persistent hypothyroid symptoms in LT4-treated patients: pitfalls of relying on TSH alone. Journal of Clinical Endocrinology & Metabolism.
• Klein, I., & Danzi, S. (2007). Thyroid disease and the heart. Circulation, 116(15), 1725–1735.
• Maia, A. L., Kim, B. W., Huang, S. A., Harney, J. W., & Larsen, P. R. (2011). Type 2 iodothyronine deiodinase in human physiology and disease. Physiological Reviews, 91(3), 943–983.
• Ojamaa, K., Klein, I., & Sabet, A. (2010). Thyroid hormone and the cardiovascular system. New England Journal of Medicine, 344(7), 501–509.
• Panicker, V., et al. (2009). Common variation in the type 2 deiodinase gene is associated with psychological well-being in patients on thyroid hormone replacement. New England Journal of Medicine, 362(2), 134–141.
• Peeters, R. P. (2017). Non-thyroidal illness and low T3 syndrome. Nature Reviews Endocrinology, 13(12), 731–741.
• Peterson, S. J., McAninch, E. A., & Bianco, A. C. (2018). Is a normal TSH synonymous with euthyroidism in levothyroxine monotherapy?. Journal of Clinical Endocrinology & Metabolism, 103(10), 3869–3879.
• Pingitore, A., Landi, P., Taddei, M. C., et al. (2005). Low triiodothyronine: A predictor of outcome in patients with heart failure. Journal of the American College of Cardiology, 45(10), 1664–1671.
• Virili, C., et al. (2016). Levothyroxine malabsorption and drug–nutrient interactions. Journal of Clinical Endocrinology & Metabolism, 101(12), 4937–4945.
• Wiersinga, W. M. (2021). Paradise lost: Thyroid hormone therapy for hypothyroidism revisited. Nature Reviews Endocrinology, 17, 507–525.
• Yen, P. M. (2019). Thyroid hormones and mitochondria: A functional crosstalk. Frontiers in Endocrinology, 10, 352.
• Pearce, E. N., et al. (2018). Iodine nutrition and thyroid disease. European Journal of Endocrinology, 178(3), R161–R177.
• Grebennikova, G., Korneev, I., & Zubarev, A. (2020). Low T3 syndrome in ICU patients with ARDS: Associations with outcomes. Journal of Critical Care, 56, 174–181.

For additional context on how I integrate these methods in practice, see my ongoing case-informed observations:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• LinkedIn: https://www.linkedin.com/in/dralexjimenez/

SEO tags: thyroid metabolism, hypothyroidism treatment, free T3 optimization, reverse T3, levothyroxine vs desiccated thyroid, liothyronine dosing, DIO2 polymorphism, integrative chiropractic care, autonomic balance, HPA axis stress, mitochondrial function, gut-liver-thyroid axis, insulin resistance and thyroid, evidence-based thyroid care, lab timing T3, HRV and thyroid, Alexander Jimenez DC APRN FNP-BC CFMP IFMCP ATN CCST